{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075915","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.772532+00:00","generated_at":"2026-05-17T15:34:05.609087+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"BioXcel presents at-home BXCL501 market opp: patients would use in 80% of episodes","bullets":["Market research shows ~3 episodes/month (36/year) per patient, vs prior 23M annual episodes estimate from claims data.","HCPs would prescribe BXCL501 for ~16% of their bipolar/schizophrenia patients based on target product profile.","Patients report they would use BXCL501 in 80% of at-home agitation episodes; pricing could reach $1,400+ per prescription.","At-home setting has no approved treatments; BXCL501 targets early intervention to prevent escalation.","SERENITY At-Home Phase 3 trial data (2,200+ episodes collected) results are upcoming."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075915","json":"https://secwatch.observer/filing/0001104659-25-075915.json","markdown":"https://secwatch.observer/filing/0001104659-25-075915.md","text":"https://secwatch.observer/filing/0001104659-25-075915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/0001104659-25-075915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925075915/tm2523088d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:34:05.609087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}